Analytical Data
-
Gene name
CLPS
- Application
-
Alternative Names
CLPS;Colipase
-
Species
Human
-
Source
E. coli
-
Tag
His tag N-Terminus
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
P04118
-
Expression Region
18-112aa
-
AA Sequence
MGSSHHHHHH SSGLVPRGSH MGSAPGPRGI IINLENGELC MNSAQCKSNC CQHSSALGLA RCTSMASENS ECSVKTLYGI YYKCPCERGL TCEGDKTIVG SITNTNFGIC HDAGRSKQ
-
Molecular Weight
13 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
CLPS (Cationic Liposome-Protein Therapeutics System) is a novel platform in the field of protein therapeutics that focuses on improving the delivery and efficacy of recombinant proteins. The rising demand for effective biopharmaceuticals has driven research into innovative drug delivery systems that can enhance the stability, bioavailability, and targeted delivery of therapeutic proteins. Traditional methods often face challenges such as low solubility, rapid degradation, and non-specific distribution within the body. CLPS overcomes these limitations by utilizing cationic liposomes as carriers that encapsulate recombinant proteins and facilitate their transport to target tissues. This approach not only protects the proteins from enzymatic degradation but also enhances their cellular uptake through electrostatic interactions. The integration of CLPS with various therapeutic proteins, including antibodies and enzymes, has shown promising results in preclinical studies, demonstrating improved therapeutic efficacy and reduced side effects. As researchers continue to explore the potential of CLPS in various medical applications, including cancer therapy and gene delivery, it holds significant promise for advancing the field of personalized medicine and developing more effective treatments for a range of diseases.
